



Biotech Capital (BTC) - ASX Announcement

8 March 2017

Biotech Capital Share Purchase Plan Completion

Biotech Capital Limited (ASX:BTC) is pleased to report that the Company's Share Purchase Plan (SPP) was well supported, having closed on 2 March 2017 raising \$595,000.

The SPP was offered to shareholders at 11 cents per share, which was the same price as the oversubscribed private placement that was completed immediately prior to the announcement of the SPP. 5,409,055 shares will be issued via the SPP. The shares for the SPP will be allotted on 8 March 2017.

The proceeds from the SPP will be used to build greater capabilities for the group in regulatory, quality and clinical services and promote the group's services to overseas clients. Through its wholly-owned subsidiary, BioImpact, the group is actively pursuing opportunities to in-license intellectual property rights to novel drugs and medical devices.

For further information contact:

Dr. Richard Treagus – Executive Chairman
Phone +61 417 520 509

About Biotech Capital

Biotech Capital Ltd ("BTC") is a listed investment fund that actively invests in entities operating in the biotechnology / life-science sectors. As a registered Pooled Development Fund (PDF), investors are generally exempt from tax on capital gains and income. BTC is listed on the Australian Stock Exchange (Code: BTC). Additional information can be found at www.biotechcapital.com.au

Forward-looking Statements

This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Biotech Capital to be materially different from the statements in this announcement.